New VP

Quote






Anonymous said:
Also heard ML is liked by the CLs . Will meet him for the first time at zone meeting later in the month.
Click to expand...

I could care less if he is a nice fuzzy type of guy, can he deliver the goods? RB is facing challenges that we never faced before and if we are not prepared our jobs could be lost. This is serious and I want to see his action plan to fend off these new competitive threats. Will know by end of year if Orexo is legit and if any new generics enter market which will drastically lower the cost of the generics. Should be interesting to see.
 






Ask him about his plans. His strategies. His priorities. What he thinks the biggest challenges and opportunities are and how he'll broach them. You'll get a song and dance and a few jokes. He is smoke and mirrors. And when things go south, he is a master finger-pointer.
 






Anonymous said:
Ask him about his plans. His strategies. His priorities. What he thinks the biggest challenges and opportunities are and how he'll broach them. You'll get a song and dance and a few jokes. He is smoke and mirrors. And when things go south, he is a master finger-pointer.
Click to expand...

It's the MC director that is smoke and mirrors - and leading execs by the nose

Better worry about that
 






























http://washpost.bloomberg.com/Story?docId=1376-MVGBTY0YHQ0X01-3K704JHALBE5UR8RP4S3JNOGMN

Reckitt Heroin Addiction Treatment Seen Luring Shire: Real M&A

Trista Kelley and Matthew BoyleOct 31, 2013 8:13 am ET


(For a Real M&A column news alert: SALT REALMNA <GO>.)

Oct. 31 (Bloomberg) -- Reckitt Benckiser Group Plc’s heroin addiction treatment could tempt drugmakers from Shire Plc to Actavis Plc to bid for the company’s pharmaceuticals unit.

Shire has been on the hunt for deals to ease reliance on its best-seller Vyvanse for attention deficit hyperactivity disorder. The Dublin-based drugmaker could be a logical buyer for the unit because it has managed competition with generics before and is adept at handling complex U.S. rules to curb illicit use of prescription medicines, Liberum Capital Ltd. said. While generic variants of Reckitt Benckiser’s Suboxone were introduced this year, the drug still dominates the U.S. market and a new injectable treatment is under development.

Shire surged to a record this week, increasing its ability to finance an acquisition with stock, and also has more cash on hand than 99 percent of specialty drug companies, according to data compiled by Bloomberg. Generic-drug makers Valeant Pharmaceuticals International Inc. and Actavis also may be interested in the RB Pharmaceuticals unit based on their experience extracting profits from assets that, like Suboxone, have declining sales, Sanford C. Bernstein & Co. said.

“There is definitely a lot of future potential in RB Pharma,” said Andrew Wood, an analyst at Bernstein in Singapore. “There must be some pharma companies out there who think that they can do even better, and take it to the next level.”

Weighing Options

Reckitt Benckiser said this month that it’s weighing options for its pharmaceuticals unit, whose main drug Suboxone treats addiction to opioids including heroin. The company, which also makes French’s mustard, Nurofen painkillers and Durex condoms, hasn’t yet hired advisers and said it plans to update investors on the progress of the review next year.
 






Selling this med would be an epic mistake. It would never be handled with the proper perspective required, if traditional pharma gets its jaws on it. Looking at how badly things have gone since traditional pharma tactics have been applied, further pharmafornication would destroy what credibility there is left.
 






My thinking is, if we are sold, part of the allure to RB is our sales force. I am not trying to blow sunshine up anyone's ass, but we have done a pretty good job in a market with a generic alternative for 4 years now (Subutex first, now generic Suboxone and Zubsolv). I would like to think that any smart company would see that and not dump us all. That being said, companies always think their people are better, so it wouldn't surprise me if they did give us the axe. And the above poster is correct, a traditional pharma company would ruin this product. Look at Zubsolv. People are jumping ship already over there, their launch is a disaster, and they have 0.3 of the market after two months. That's because they took a traditional pharma approach to selling in this disease space. Coverage is their only savior now.
 






Your formulary coverage will evaporate into thin air on January 1. You were only told about CVS because CVS sent out a press release. Many formularies have been lost for 2014. RBP isn't telling you because they are trying to keep the panic at a minimum.

Anyone not looking now for 2014 is fooling themselves.
 






























He's got attitude, will fight the status quo, won't put up w/BS & he knows we have to grow. He will get us to grow our territories or he'll get people who will. We have to expand the market w/Film. Only Film Volume will bring in the $$$$.
 
























Top Bottom
Back
Quote